Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib

ConclusionsThe combined analysis of these studies confirms the objective tumor responses and improvements in PFS observed in the initial phase III trial, providing further support for the clinical benefit of sunitinib in patients with advanced panNETs.ClinicalTrials.gov IdentifiersNCT00428597 and NCT01525550.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research